| Autor: |
Matthew J. Gorman, Nita Patel, Mimi Guebre-Xabier, Alex L. Zhu, Caroline Atyeo, Krista M. Pullen, Carolin Loos, Yenny Goez-Gazi, Ricardo Carrion, Jr., Jing-Hui Tian, Dansu Yuan, Kathryn A. Bowman, Bin Zhou, Sonia Maciejewski, Marisa E. McGrath, James Logue, Matthew B. Frieman, David Montefiori, Colin Mann, Sharon Schendel, Fatima Amanat, Florian Krammer, Erica Ollmann Saphire, Douglas A. Lauffenburger, Ann M. Greene, Alyse D. Portnoff, Michael J. Massare, Larry Ellingsworth, Gregory Glenn, Gale Smith, Galit Alter |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Cell Reports Medicine, Vol 2, Iss 9, Pp 100405- (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2666-3791 |
| DOI: |
10.1016/j.xcrm.2021.100405 |
| Popis: |
Summary: Recently approved vaccines have shown remarkable efficacy in limiting SARS-CoV-2-associated disease. However, with the variety of vaccines, immunization strategies, and waning antibody titers, defining the correlates of immunity across a spectrum of antibody titers is urgently required. Thus, we profiled the humoral immune response in a cohort of non-human primates immunized with a recombinant SARS-CoV-2 spike glycoprotein (NVX-CoV2373) at two doses, administered as a single- or two-dose regimen. Both antigen dose and boosting significantly altered neutralization titers and Fc-effector profiles, driving unique vaccine-induced antibody fingerprints. Combined differences in antibody effector functions and neutralization were associated with distinct levels of protection in the upper and lower respiratory tract. Moreover, NVX-CoV2373 elicited antibodies that functionally targeted emerging SARS-CoV-2 variants. Collectively, the data presented here suggest that a single dose may prevent disease via combined Fc/Fab functions but that two doses may be essential to block further transmission of SARS-CoV-2 and emerging variants. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
